Merck bets $50M on Saturnus to pioneer precision cardiology for rare heart diseases

Merck is expanding its cardiometabolic business into precision cardiology through a new partnership with Saturnus. The deal targets rare genetic cardiomyopathies, a group of serious inherited heart diseases with limited treatment options. Saturnus focuses on developing first-in-class therapies for these conditions using targeted gene modulation. The collaboration begins with a $50 million upfront payment from Merck to fund Saturnus’ research. This investment supports the company’s goal of building a pipeline of novel medicines for genetic cardiomyopathies. Merck also secures a minority equity stake in Saturnus and exclusive rights to acquire the company later through a pre-agreed option payment, with additional success-based earnouts.

Saturnus, led by CEO Rick Dewey, aims to address unmet medical needs in rare heart diseases. Dewey, an entrepreneur-in-residence at Versant Ventures, highlighted that the launch aligns with Versant’s strategy of partnering with pharma to develop innovative treatments. Versant has a history of such company-creation deals, including BlueRock Therapeutics and Inception 5, which later led to acquisitions.

The agreement reflects Merck’s 2025 plan to rebuild healthcare growth through a balanced pipeline, combining external innovation with internal assets. Build-to-buy deals like this allow pharma companies to influence a biotech’s early development while delaying full acquisition until key milestones are met. The partnership gives Merck access to Saturnus’ gene modulation therapies for rare cardiomyopathies. Saturnus gains funding and strategic support to advance its pipeline. The structure of the deal allows Merck to assess progress before committing to a full takeover.